Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease.
Inflammatory bowel diseases are treated in some cases by local administration of anti-inflammatory drugs. Local delivery of drugs in the colon following oral administration may lead to improved efficacy/side-effect profiles and may improve patient compliance. This review covers a number of issues important in the design of oral delivery systems of glucocorticosteroids for local therapy of colonic inflammation. The choice of specific glucocorticosteroids is based on the drug's physicochemical and pharmacological properties. The conditions under which an orally administered glucocorticosteroid (or other drug) must be delivered to treat ulcerative colitis are also discussed. These conditions include variations in local pH, transit throughout the gastrointestinal tract, the potential role of gut microflora, and drug dissolution in both the healthy and diseased large intestine. The effective delivery of topically-active glucocorticosteroids in ulcerative colitis and Crohn's colitis patients is complex, but if successful could improve their usefulness.
CIBUS Pharmaceutical Inc., California 94026-1226, USA. drfriend1@aol.com
D R
DR
Friend
D000284:Administration, Oral; D000285:Administration, Rectal; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D019540:Area Under Curve; D019819:Budesonide / Q000493:pharmacokinetics / Q000627:therapeutic use; D005746:Gastric Emptying / Q000187:drug effects; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006207:Half-Life; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D019819:Budesonide